Teva v. Eli Lilly: Teva Argues Lilly Is Infringing Migraine Drug Patent in the United States

2 Pages Posted: 21 Aug 2018

See all articles by Riccardo Tremolada

Riccardo Tremolada

Harvard University, Law School, Students; Cleary Gottlieb Steen & Hamilton LLP; gLAWcal - Global Law Initiatives for Sustainable Development

Date Written: December 1, 2017

Abstract

This complaint constitutes the last stage of a race involving several pharmaceutical companies competing to develop new products to treat migraines. Given the scarce availability of preventive therapeutic options, the market potential for innovative calcitonin gene-related peptide based drugs for the treatment of migraine – such as Fremanezumab and Galcanezumab – is particularly relevant, estimated around $8 billion to $10 billion.

Keywords: Pharmaceutical; Intellectual Property; Patents; Patent Infringement.

Suggested Citation

Tremolada, Riccardo, Teva v. Eli Lilly: Teva Argues Lilly Is Infringing Migraine Drug Patent in the United States (December 1, 2017). Harvard Journal of Law & Technology, 2017, Available at SSRN: https://ssrn.com/abstract=3224391

Riccardo Tremolada (Contact Author)

Harvard University, Law School, Students ( email )

1563 Massachusetts Avenue
Cambridge, MA 02138
United States

Cleary Gottlieb Steen & Hamilton LLP ( email )

Washington DC, NY 10006
United States

gLAWcal - Global Law Initiatives for Sustainable Development ( email )

52 East Quay, Wapping Quay
Liverpool, L3 4BU
United Kingdom

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
4
Abstract Views
67
PlumX Metrics